TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.00700nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.00700nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.00800nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.00900nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.00900nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.00900nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataKd: 0.0100nMAssay Description:Binding affinity to FLT3-ITD-D835V mutant (unknown origin) assessed as dissociation constantMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0100nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0100nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0100nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0110nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0110nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0110nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [F691L](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0120nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0120nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [F691L](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0120nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0120nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0140nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0140nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataKd: 0.0154nMAssay Description:Binding affinity to FLT3 ITD/F691L double mutant (unknown origin) by KINOMEscan assayMore data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0160nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0160nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0170nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataKd: 0.0170nMAssay Description:Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assayMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataKd: 0.0170nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0180nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0200nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0200nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0210nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0210nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0230nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0230nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataKd: 0.0240nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataKd: 0.0250nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0250nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0250nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [F691L](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0250nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0250nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataKd: 0.0290nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [F691L](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0300nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0300nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [F691L](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0330nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataKd: 0.0340nMAssay Description:Inhibition of 5-LOX in A23187-stimulated human blood PMNL assessed as reduction in lipoxygenase products formation in presence of arachidonic acid pr...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0340nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0340nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataKd: 0.0350nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [R834Q](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0360nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0360nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835H](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0380nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0410nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
